Today’s return of mandatory face masks in shops and other measures will “buy us time” as scientists assess the threat level of Omicron, Boris Johnson has said.
The prime minister promised that the latest restrictions, which also include travel restraints, will be reviewed in three weeks when the government hopes to have better information about the effectiveness of vaccines against the new Covid-19 variant.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
‘Evolutionary leap’
Omicron is thought to have evolved from an older strain of the virus known as B.1.1, which has now nearly disappeared, said The Wall Street Journal (WSJ). “It probably spent many months lurking in an immunocompromised person – maybe an HIV/AIDS patient – slowly racking up evolutionary advantages.”
When it was discovered in South Africa after a surge in Covid cases, scientists were “startled”, said Ben Spencer, science editor at The Sunday Times. It had 50 mutations, including 30 on its spike protein, more than double that of the Delta variant. “This was not just a gradual shift, it was an evolutionary leap,” said Spencer.
The fear is that antibodies from the most common vaccines will not recognise the spike protein efficiently and “our hard-won immunity might be side-stepped”, he explained. Ten of the Omicron mutations were also on a section of the spike protein that attaches to human cells, and the theory is that these make it more transmissible. Delta only had two.
While the “genomics do not look good”, this is so far a theoretical risk, said Spencer.
Inside the labs
“Scientists have reacted more quickly to Omicron than to any other variant,” said The New York Times (NYT). They were quick to analyse samples in South Africa, where cases were rising, and alert the world to the new mutation. Since then they have been rushing to test vaccines against it.
“Dozens of teams worldwide – including researchers at Pfizer-BioNTech and Moderna – have joined the chase,” said the NYT.
Penny Moore, a virologist at the National Institute for Communicable Diseases in Johannesburg, South Africa, “is perhaps the furthest along in testing”, said the newspaper. She and her team are “preparing to test blood from fully immunized people against a synthetic version of the Omicron variant”. They will also look at the immunity offered by another component of the immune system called T cells.
Another team at the Africa Health Research Institute is growing a live version of the variant to test.
Dr Stephen Hoge, Moderna’s president, has called Omicron “a Frankenstein mix of all of the greatest hits” and said “it just triggered every one of our alarm bells”. Both Moderna and Pfizer are preparing to reformulate their shots if necessary, potentially within three months.
The NYT said this would be a “miraculous feat”, although added that “the prospect of producing and distributing them raises daunting questions”.
The wait
Moore told Nature her team was “flying at warp speed”, but that results would take around two weeks.
The science journal said researchers are also studying whether Omicron “causes disease that is more severe or milder than that produced by other variants”.
Patients currently infected with Omicron will need “days or weeks” to determine how bad their disease becomes, said the WSJ.
In the UK, Health Secretary Sajid Javid vowed that new measures will not be kept in place for “a day longer than necessary” if Omicron turns out to be milder than expected.
As the wait continues Tom Whipple, science editor at The Times, said overreaction was preferable to underreaction: “Time and time again governments have learnt the hard way that if you wait for perfect data, by the time it arrives it is too late.”
But he added that it was “still perfectly plausible” that when the findings emerge “we might yet discover that the world has indeed overreacted and – happily – merely ended up looking a bit silly”.
-
Rothermere’s Telegraph takeover: ‘a right-leaning media powerhouse’Talking Point Deal gives Daily Mail and General Trust more than 50% of circulation in the UK newspaper market
-
The US-Saudi relationship: too big to fail?Talking Point With the Saudis investing $1 trillion into the US, and Trump granting them ‘major non-Nato ally’ status, for now the two countries need each other
-
Crossword: November 30, 2025The daily crossword from The Week
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sickspeed read The FDA set stricter approval standards for booster shots
-
RFK Jr.: A new plan for sabotaging vaccinesFeature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Five years on: How Covid changed everythingFeature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
HMPV is spreading in China but there's no need to worryThe Explainer Respiratory illness is common in winter
